At Takeda Oncology, we aspire to cure?#cancer. Below, hear from our leaders about how we’re positioned to elevate the standard of cancer care for patients globally through our cutting-edge science, strategic partnerships and programs that enable access to our medicines.? ? To learn more, visit:?www.takedaoncology.com
关于我们
Takeda Oncology, the Global Oncology Business Unit of Takeda Pharmaceutical Company Limited, is structured to ensure a tight connection from research to development to commercialization and rapidly meet the needs of the cancer community, optimizing our ability to bring transformative medicines to market. Built on a legacy foundation and structured for agility, our leaders have proven experience to drive future growth. We’ve demonstrated leadership in the treatment of hematologic cancers and solid tumors, and we’re now leveraging that expertise to advance cutting-edge science through multiple platforms, partnerships and therapeutic approaches. We are focused on collaborating with leading scientific teams around the globe to accelerate remarkable innovation, including by leveraging the power of innate immunity to enhance and broaden the impact of immunotherapy. We complement our deep in-house expertise with a network of symbiotic external partnerships to unlock the most promising science wherever it emerges. We fuel our relationships with academic, biotechnology and pharmaceutical partners with mutual respect, shared knowledge, scientific rigor and agility to find the best way to attack cancer. Takeda Oncology: We aspire to cure cancer, with inspiration from patients and innovation from everywhere. For more information, visit www.takedaoncology.com. If you are interested in learning more about current career opportunities, please visit the Takeda Pharmaceuticals Career Page. Review our social media community guidelines: https://www.takedaoncology.com/social-media-policy/
- 网站
-
https://www.takedaoncology.com
Takeda Oncology的外部链接
- 所属行业
- 制药业
- 规模
- 1,001-5,000 人
- 总部
- Cambridge，MA
- 类型
- 上市公司
- 创立
- 1993
- 领域
- oncology、drug development和biotechnology
地点
-
主要
获取路线
40 Landsdowne St.
US，MA，Cambridge，02139
Takeda Oncology员工
动态
-
Join us at the?ESMO - European Society for Medical Oncology?Annual Meeting for a Takeda Oncology-sponsored medical symposium to hear the latest from #oncology leaders on navigating treatment selection for people living with metastatic colorectal cancer (#mCRC). View details on this Saturday’s symposium?here: https://lnkd.in/gcnc636q #ESMO24 #crcsm?
-
-
We had a great time at the Pan-Mass Challenge this weekend. Thank you to our riders for cycling to cure cancer, all our colleagues who volunteered and to those who cheered us on! See #TeamTakeda in action at #PMC2024 below!?
-
-
We are pleased to enter a new?partnership with?BostonGene, a leading provider of #ArtificialIntelligence (AI)-driven molecular and immune profiling solutions. This partnership will?enable us to use cutting-edge technology to better understand our investigational therapies at the earliest stages, optimizing their development for people living with #cancer. Find out more: https://lnkd.in/g3kJes6f
-
-
#TeamTakeda is back on the road for the 2024 Pan-Mass Challenge! Hear why representing #TeamTakeda at the #PMC2024 is more than just a ride for Julie. #OneInABillion #WhyIRide
For team members like Julie, riding with #TeamTakeda allows her to embrace two important identities within the #cancer community as both a dedicated professional and caring family member. Hear why she's proud to honor her brother Ryan at this year’s Pan-Mass Challenge. #PMC2024 | #OneInABillion
-
We’re pleased to share the European Commission has approved a therapy for adult patients with previously treated metastatic #ColorectalCancer (#mCRC) throughout the European Union, Iceland, Liechtenstein and Norway. Learn more about this announcement: https://lnkd.in/gJjVNcut
-
With more effective options than ever before, there is a greater need to collectively evolve how we select #cancer treatments for individuals with varied life experiences. See why Awny Farajallah, MD, FACP, Chief Medical Officer, Global Oncology, says the future of cancer care considers real-world factors alongside traditional clinical standards: https://lnkd.in/ePms_URR
-
-
We’ve announced an option agreement with Ascentage Pharma that will allow us to enter into a future exclusive global license agreement for its investigational therapy currently in development for #ChronicMyeloidLeukemia (CML) and other #HematologicalCancers. If exercised, the option would allow Takeda to secure rights to develop and commercialize the therapy in all indications and territories outside of mainland China, Hong Kong, Macau, Taiwan and Russia. Read more here: https://lnkd.in/emdra3rS
Takeda Signs Option Agreement with Ascentage Pharma
takedaoncology.com
-
Cancer is a looming threat that affects all of us, with incidence projected to increase over the next 25 years, according to the American Cancer Society. Awny Farajallah, MD, FACP, Chief Medical Officer, Global Oncology, says we need solutions now. Read more about how we can bring these solutions to patients faster by rethinking #ClinicalTrial design. Learn more in STAT: https://lnkd.in/evpx8r-x
-
A difficult decision is always the right one if it aligns with your #values. Pallavi Garg, Head, Global Oncology Products and Pipeline Strategy, shares how, amidst the rapid pace of change in #healthcare, our team's collective purpose, vision and values continue to persevere. Learn how we let our ethics and values inspire a sense of urgency and guide our path to curing #cancer: https://lnkd.in/dw8izTZe